---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-117704"
form_type: "8-K"
ticker: "ALMS"
cik: "0001847367"
company_name: "ALUMIS INC."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:05:09.481931+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Alumis reports Q3 net loss of $93.1M; cash of $361.9M funds operations into 2026

## Summary
- Net loss of $93.1M in Q3 2024 vs $43.4M in Q3 2023; R&D expenses rose to $87.8M from $37.8M, including $23M milestone payment for FronThera acquisition.
- Cash and marketable securities of $361.9M as of Sept 30, 2024, expected to fund operations into 2026.
- ESK-001 Phase 3 ONWARD psoriasis trials on track; topline results expected H1 2026. Phase 2b SLE data expected 2026.
- A-005 Phase 1 data expected by year-end 2024; Phase 2 MS trial initiation planned 2025.
- Presented EADV data: ESK-001 40mg BID achieved 93% PASI 75 at 28 weeks (observed); supports ongoing Phase 3 dose.

## SEC filing metadata
- accession: 0001104659-24-117704
- form_type: 8-K
- ticker: ALMS
- cik: 0001847367
- company_name: ALUMIS INC.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847367/000110465924117704/0001104659-24-117704-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847367/000110465924117704/tm2428191d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-117704
- JSON: https://secwatch.observer/filing/0001104659-24-117704.json
- Plain text: https://secwatch.observer/filing/0001104659-24-117704.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.